IP Library Granted Patent US 8,796,215
Granted Patent B2
US 8,796,215 · App. 13/676,649 · Granted Aug 5, 2014

Neurotrophic peptides

Inventors: Khalid Iqbal (Staten Island, NY); Inge Grundke-Iqbal (Staten Island, NY)
Assignee: Research Foundation For Mental Hygiene, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,796,215
App. No.
13/676,649
Granted
Aug 5, 2014
Kind
B2
Abstract

The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C-and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Alzheimer's disease.

Claims (11)

1. A method of treating a subject having Alzheimer's disease comprising the step of administering a therapeutic amount of a neurotrophic peptide consisting of the amino acid sequence selected from the group consisting of VGDGGLFEKKL (SEQ ID NO: 1), GDGGLFEK (SEQ ID NO: 5), GLFEKKLW (SEQ ID NO: 6), VGDG (SEQ ID NO: 7), GDGG (SEQ ID NO: 8), DGGL (SEQ ID NO: 9), and GGLF (SEQ ID NO: 10).

2. The method of claim 1 , wherein said neurotrophic peptide is administered peripherally.

3. The method of claim 1 , wherein said neurotrophic peptide is administered subcutaneously.

4. The method of claim 1 , wherein said neurotrophic peptide is administered orally.

5. The method of claim 1 , wherein said neurotrophic peptide is administered intraperitoneally.

6. A method of treating a subject having Alzheimer's disease comprising the step of administering a therapeutic amount of a neurotrophic peptide consisting of the amino acid sequence DGGL (SEQ ID NO: 9) bound to an adamantane building block.

7. The method of claim 6 , wherein said adamantane building block is bound to a C-terminus of said neurotrophic peptide.

8. The method of claim 6 , wherein another adamantane building block is bound to an N-terminus of said neurotrophic peptide.

9. The method of claim 6 , wherein said adamantane building block comprises 3-aminoadamantane-1-carboxylic acid.

10. The method of claim 6 , wherein said neurotrophic peptide bound to said adamantane building block consists of the sequence Ac-DGGL A G-NH 2 (SEQ ID NO: 12).

11. The method of claim 6 , wherein said neurotrophic peptide bound to said adamantane building block consists of the sequence Ad-CO-DGGL A G-NH 2 (SEQ ID NO: 13).

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 18, 2013
From: INSTITUTE FOR BASIC RES IN DEV DISABIL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031228/0721 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2012
From: IQBAL, KHALID; GRUNDKE-IQBAL, INGE
To: THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.
Reel/Frame 029296/0570 →
Priority Claims (1)
EP 07450050 · Mar 16, 2007 · regional
Continuity (3)
Continuation In Part 13044323 · Mar 9, 2011
Continuation In Part 12531616
Related Publication 20130157946A1 · Jun 20, 2013